Department of Urology and Pediatric Urology, Julius-Maximilians-University Medical Center, Würzburg, Germany.
Eur Urol. 2013 Jan;63(1):36-44. doi: 10.1016/j.eururo.2012.08.061. Epub 2012 Sep 5.
Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach.
To critically review the recent data on the management of NMIBC to arrive at a general consensus.
A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched.
The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies.
Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.
本研究旨在通过循证方法总结第二次膀胱癌咨询会议关于非肌层浸润性膀胱癌（NMIBC）诊断和治疗选择的建议。
通过对 NMIBC 管理的最新数据进行批判性回顾，达成普遍共识。
对涉及 NMIBC 诊断、手术、膀胱内化疗和随访治疗的原始文章进行详细的 Medline 分析。还搜索了过去 5 年主要会议的会议记录。
主要发现以循证方式呈现。我们分析了大型回顾性和前瞻性研究。
分期为 Ta、T1 和原位癌（CIS）的膀胱尿路上皮癌，也称为 NMIBC，对泌尿外科护理提出了极大不同但同样具有挑战性的要求。一方面，Ta 低级别、低复发率和低进展率需要风险适应治疗和监测，以在最小化治疗相关负担的同时提供全面护理。另一方面，Ta 高级别、T1 和 CIS 进展的倾向需要强化护理，并及时考虑根治性膀胱切除术。
